Valorisation-recherche, Limited Partnership

Valorisation Hsj, Limited Partnership

Other

Universitéde Montreal

Theratechnologies Inc.

Hopital Sainte-justine

Rsem, Limited Partnership

Hospital Sainte-justine

Valorisation Hsj, Societe En Commandite

Valorisation-rechereche Société En Commandite

Valo Hsj, Limited Partnership

Valorisation-recherche, Societe En Commandite

Sylvain Chemtob

William A Lubell

Krishna G Peri

Huy Ong

Caroline Proulx

Florian Sennlaub

Damien Boeglin

Zohreh Sajjadi

David Sabatino

Christiane Quiniou

Eryk Thouin

Michel Potier

Martin Beauchamp

Felix Polyak

Damon Smith

Stephane Alain Laporte

Piotr Kujawa

William D Lubell

Bradut Mitrasca

Terence E Hebert

Samy Omri

Robert Hopewell

Karl A Hansford

Kim Beauregard

Yesica Garcia-Ramos

Danae Tassy

Xin Hou

Eugenie Goupil

Carine B Bourguet

Audrey Claing

Ngoc-Duc Doan

Alexander Cunningham

Anna-Maria Szczesniak

Robert Zalega

Melanie Kelly

An azapeptide compound of Formula I:A-(Xaa)-N(R)&#x2014;N(R)&#x2014;C(O)-(Xaa')-B &#x2003;&#x2003;I.

Azapeptides as CD36 binding compounds

An azapeptide compound of Formula I:A-(Xaa)-N(R)&#x2014;N(R)&#x2014;C(O)-(Xaa')-B&#x2003;&#x2003;I.

The invention relates to compositions which are useful for inhibiting prostaglandin Freceptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.

[object Object]

Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed. Use of such peptidomimetics for modulating the activity of CD36 or IL-1 receptor in a cell, and for treating CD36- or IL-1-related disease, disorder or condition is also described.

Peptidomimetics comprising N-amino cyclic urea residues and uses thereof

Prostaglandin-F2 alpha (PGF2&#x3b1;) receptor (FP) modulators of formula I, as well as the use of PGF2&#x3b1; receptor modulators for the treatment of conditions associated with FP activity such as preterm labor and colorectal cancer, are disclosed.

Prostaglandin-F2 alpha receptor modulators and uses thereof

Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases. This invention also discloses an isolated compound having an IL-1R antagonist activity, said compound being selected from the group consisting of: a peptide comprising the amino acid sequence RYTPELX, wherein R, Y, T, P, E, L, refer to their corresponding amino acids, and X is selected from no amino acid and alanine (A); and a derivative of (a) wherein the derivative incorporates one, two or three amino acid modification selected from an amino acid addition, deletion or substitution in the RYTPEL portion of the peptide, and wherein said derivative maintains its antagonist IL-1R activity.

Interleukin-1 receptor antagonists, compositions, and methods of treatment

An azapeptide derivative of growth hormone releasing peptide (GHRP) of Formula I: A-(Xaa)-N(R)&#x2014;N(R)&#x2014;C(O)-(Xaa')-B which binds to CD 36.

The present invention relates to a composition of matter comprising novel prostaglandin E2 receptor antagonists, and their use in treatments for regulating the fluid filtration in the kidney, preventing bone mineral loss in osteoporosis and dental disease and additionally, closure of ductus arteriosus (DA) in premature infants or fetal animals. Additionally, the compositions include linear peptides, peptide analogs, and peptidomimetics.

Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed. Also disclosed are methods for treating patients with a disease or condition associated with abnormal cytokine receptor mediated function or activity such as inflammatory, autoimmune and vascular diseases.

Cytokine receptor modulators and method of modulating cytokine receptor activity

The present invention relates to a new class of G protein-coupled receptor agonist or antagonist, which specifically binds to the receptor protein structural elements, thus altering signal transmission and subsequent physiological effects. Described herein are peptide sequences derived from the G protein-coupled receptor protein, produced by chemical methods as selective inhibitors of signal transduction associated with stimulation of the receptor by its ligand. Such peptides or molecules derived from their primary, secondary or tertiary structures may be used as effective tocolytics for the prevention of premature labor or be used for the treatment of dysmenorrhea.

Peptide antagonists of prostaglandin F2&#x3b1; receptor

The present invention relates to a new class of G-protein-coupled receptor antagonists which bind to the intracellular molecular interface between the receptor and the G-protein, thus hampering signal transduction. The present invention describes peptide sequences derived from the prostaglandin receptor F,and the G-protein, G,protein. produced by molecular biology techniques or chemical synthesis, as selective inhibitors of signal transduction involved in the stimulation of this receptor. Such peptides or molecules derived from their primary, secondary and tertiary structures may be used as effective tocolytics for the prevention of premature labor or be utilized for the treatment of dysmenorrhea.

Antagonists of G-protein-coupled receptor

The present invention relates to a new class of G-protein-coupled receptor antagonists which bind to the intracellular molecular interface between the receptor and the G-protein, thus hampering signal transduction. The present invention describes peptide sequences derived from the prostaglandin receptor F.sub.2.alpha. and the G-protein, G.alpha.q protein, produced by molecular biology techniques or chemical synthesis, as selective inhibitors of signal transduction involved in the stimulation of this receptor. Such peptides or molecules derived from their primary, secondary and tertiary structures may be used as effective tocolytics for the prevention of premature labor or be utilized for the treatment of dysmenorrhea.

Growing community of inventors

Cote St-Luc, Canada

Sylvain Chemtob